A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer
Scagliotti, Giorgio V × Germonpre, Paul Bosquee, Leon Vansteenkiste, Johan Gervais, R Planchard, David Reck, Martin De Marinis, Filippo Lee, Jin Soo Park, Keunchil Biesma, Bonne Gans, Steven Ramlau, R Szczesna, Aleusandra Makhson, A Manikhas, G Morgan, Bruno Zhu, Y Chan, Kai C von Pawel, Joachim #
Lung Cancer vol:68 issue:3 pages:420-426
This is a phase II randomized study to evaluate the efficacy and safety of bortezomib and pemetrexed alone or in combination, in patients with previously treated advanced non-small-cell lung cancer (NSCLC). The primary end point was assessment of response rate.